Eurofins Regulatory & Consultancy Services Italy

Happy New Year! The Eurofins network wishes you a happy and healthy 2025. ✨ #Eurofins #TestingforLife #HappyNewYear

🎇 🎄 As we conclude this remarkable year, we are proud to reflect on our achievements. 💯 🎖️ Over 250 clients have placed their trust in our consultancy services, resulting in the successful completion of more than 750 projects impacting the pharmaceutical, biologics, cell and gene, chemicals and biocides industry. Our numerous workshops, conference presentations, and poster sessions stand as a testament to our success. 🤝 We extend our heartfelt gratitude for being part of this journey. Together, we have achieved remarkable milestones, and we look forward to even greater accomplishments in 2025. Here's to a future filled with continued success and innovation! #regulatory #consulting #pharma #biopharma #biologics #advancedtherapies #chemicals #biocides

"🌟 Dopo tre edizioni di grandissimo successo in Europa, il nostro Workshop esclusivo ha una nuova data in Italia! 🇮🇹 Non perdere l'opportunità di partecipare a questo evento esclusivo e migliorare le tue competenze nel settore farmaceutico. 🚀 Unisciti a noi per una serie di sessioni coinvolgenti e pratiche su Extractables and Leachables e Container Closure Integrity Testing. Punti salienti del workshop: 📍 Sessioni complete su Extractables and Leachables 📍 Formazione approfondita su Container Closure Integrity Testing 📍 Valutazione tossicologica 📍 Attività pratiche e risoluzione di problemi in tempo reale 📍 Opportunità di networking con esperti del settore 🎙️ Speakers: Simone Carrara, Francesco Tessari, Francesca Calò PhD and Eleonora Lostaglio, Daniele Zarini. Iscriviti ora: 📝https://lnkd.in/dHnUADKf Altre edizioni: 💡 Belgium: https://lnkd.in/dvnBg6dJ 💡 Spain: https://lnkd.in/dNsFZVSF 💡 Sweden: https://lnkd.in/dgBrtP2P 🎧 Per maggiori informazioni sui nostri servizi: Eurofins.Biolab@bpt.eurofinseu.com 💻: https://lnkd.in/d8JN9UMw #extractables #leachables #testing #biopharma #CCIT

🔔#EU_CLP - Are you distributing hazardous mixtures? You may need to submit information to the relevant poison centres! 📑⚠️ 🚨 CLP revision defines new role for distributors in poison centre notifications. Companies that relabel, rebrand or retail hazardous mixtures – are now duty holders and may need to submit information on hazardous mixtures to poison centres. This is needed unless all information is already available to the relevant authorities. Read more: https://lnkd.in/dtqwMRmx 📑 All duty holders must make sure that a notification exists for their mixtures and keep them up to date. In addition, companies must inform poison centres of any changes that could be relevant for an emergency health response (eg. packaging type, product category or any contact details) Need support? Our regulatory team offers a range of services to help you comply with the updated CLP Regulation, including: ✅ Notification management: We handle the submission of notifications to poison centres for your hazardous mixtures including also any changes to your mixtures, such as packaging type, product category, or contact details ✅  Regulatory updates: We keep you informed about any changes in regulations that might affect your products ✅  Consultation and Support: We provide expert advice and support to help you understand and meet your regulatory obligations Contact us today: consultancyitaly@bpt.eurofinseu.com #regulatory #RegulatoryCompliance #Chemicals #ChemicalSafety

🌟7th Conference and Workshop on Biocides! Join this must-attend event to expand your horizons on the latest regulatory updates, compliance strategies, and industry insights. 🌟   🛩️ Join us in Milan to: 💬 Engage with competent authorities who will answer all your questions on biocidal products 🎯 Gain valuable insights from a distinguished panel of speakers 🤝 Network with industry professionals and peers  📈 Stay updated on the latest trends and regulations in the biocides sector   Are you ready to stay ahead in the field? Register now: https://lnkd.in/ddMMigdx   Leading Eurofins team: Michele Cavalleri, Linda Musitelli, Simone Bertolini from Eurofins Regulatory & Consultancy Services Italy For more informations on the event: EurofinsBiolab@bpt.eurofinseu.com  For registrations: training-italy@bpt.eurofinseu.com #BiocidesConference #SaveTheDate #BiocidalProducts #BPR

🔔 #EU_CLP! The updated Classification, Labelling and Packaging (CLP) regulation enters into force ⌚ The updated CLP regulation aims to better identify and classify hazardous #chemicals, as well as improve the communication on chemical hazards. Companies should assess and review their portfolio of substances and mixtures and inform ECHA about any new classifications. More details here: https://lnkd.in/dJmR4y3Z Are you impacted by the changes? 🎯 Unlock the benefits of timely compliance and avoid costly delays with our expert assistance. Contact us now to ensure your success and stay ahead of the curve! 📧 consultancyitaly@bpt.eurofinseu.com #regulatory #RegulatoryCompliance #SafetyFirst #ChemicalSafety

🌟Join us for the 7th Conference Workshop on Biocides on March 5-6, 2025, in Milan! This event is a must-attend for anyone involved in biocidal products, offering the latest regulatory updates, compliance guidelines, and industry insights. 🌟 Join us to: 💬 Engage with competent authorities who will answer all your questions on biocidal products 🎯 Gain valuable insights from a distinguished panel of speakers 🤝 Network with industry professionals and peers 📈 Stay updated on the latest trends and regulations in the biocides sector Are you ready to stay ahead in the field and network with industry experts? Register now: https://lnkd.in/ddMMigdx More speakers to be confirmed soon! For more informations on the event: EurofinsBiolab@bpt.eurofinseu.com For registrations: training-italy@bpt.eurofinseu.com #BiocidesConference #SaveTheDate #BiocidalProducts #BPR

News from #ECHA: REF-11 Findings: 35% of SDS Found Non-Compliant ⚠️ Inspectors in 28 EU-EEA countries checked over 2,500 safety data sheets (SDS) to enforce new 2023 requirements. They found 35% of SDS were non-compliant, mainly due to missing or incomplete information. Read more: Key issues included: ⚠️Missing information on nanoforms (67%) ⚠️Missing information endocrine disrupting properties (48%) 📉 Data quality issues (27%) 🛑 Lack on required exposure scenarios (18%) Need support? Choose our services for unparalleled expertise in compliance, precise and reliable data, and seamless regulatory alignment, ensuring your safety data sheets are always accurate and up-to-date.   Services we offer: ✅ Enhance Compliance: Regularly review and update SDS to meet regulatory requirements ✅ Address Information Gaps: Include comprehensive data on nanoforms and endocrine disrupting properties ✅ Strengthen Supply Chain: Ensure prompt distribution of SDS to all supply chain recipients ✅ Continuous Improvement: Update SDS based on feedback and new information for ongoing compliance and quality Contact us today: consultancyitaly@bpt.eurofinseu.com #SafetyDataSheets #Nanoforms #EndocrineDisruptors #chemicals #biocides

🚀 With a fully booked room of enthusiastic participants, we're off to a great start! 🚀 Our workshop on Extractables & Leachables and Container Closure Integrity Testing is underway in Sweden, and the energy is fantastic! 💡📈 Looking forward to a productive and insightful session with all participants. Thank you to Eurofins BioPharma Product Testing Sweden for the great organisation. From 🇧🇪 Belgium to 🇪🇸 Spain to 🇸🇪 Sweden: next stop, 🇮🇹 Italy! Mark your calendars for 5 February 2025: https://lnkd.in/d_V3TWq4 #extractables #leachables #testing #biopharma #CCIT #chemistry

🧬📢 New FDA Draft Guidance: A Must-Read for Gene Therapy Developers! In November 2024, the FDA released a draft document addressing FAQs for developing cellular and gene therapy products. This guidance aims to help the industry navigate common challenges and covers key areas such as: 🧬 FDA Interactions: IND submissions, meeting types, amendments, and expedited programs 🧬 CMC Considerations: Product characterisation, critical quality attributes, analytical methods, process validation, manufacturing changes, and stability 🧬 Non-Clinical Studies: Animal model selection, proof-of-concept studies, toxicology, and pharmacology 🧬 Human Trials: Trial design, endpoint selection, and safety data Read full document: https://lnkd.in/es726_NG Need support?  🤝 With our extensive expertise in CMC/quality both regulatory and testing support, as well as our pre-clinical knowledge, we are uniquely positioned to help you navigate these new guidelines effectively and elevate your development of cellular and gene therapy products. What challenges have you faced in developing gene therapy products? Let us know in the comments! 👇 Innovate with confidence and contact us today: consultancyitaly@bpt.eurofinseu.com #ATMP #CellTherapy #FDA #CGT #DrugDevelopment #GeneTherapy